{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:53:16Z","timestamp":1792270396659,"version":"4.4.0"},"reference-count":280,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01300","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T03:36:45Z","timestamp":1542080205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":805,"title":["Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium"],"prefix":"10.3389","volume":"9","author":[{"given":"Luca","family":"Falzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/jm00250a016","article-title":"Inhibitors of polyamine biosynthesis. 1. Alpha-methyl-(plus or minus)-ornithine, an inhibitor of ornithine decarboxylase","volume":"17","author":"Abdel-Monem","year":"1974","journal-title":"J. Med. Chem"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/80.20.1605","article-title":"Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice","volume":"80","author":"Aboud-Pirak","year":"1988","journal-title":"J. Natl. Cancer Inst"},{"key":"B3","unstructured":"Animal Cell Technology Industrial Platform. Monoclonal Antibodies Approved by the EMA and FDA for Therapeutic Use status (2017)2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors","volume":"29","author":"Adams","year":"2007","journal-title":"Clin. Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/bs.podrm.2015.12.002","article-title":"Dacarbazine","volume":"41","author":"Al-Badr","year":"2016","journal-title":"Profiles Drug. Subst. Excip. Relat. Methodol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40487-016-0030-2","article-title":"Network meta-analysis of progression-free survival and overall survival in first-line treatment of BRAF mutation-positive metastatic melanoma","volume":"4","author":"Amdahl","year":"2016","journal-title":"Oncol. Ther"},{"key":"B7","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","article-title":"Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate","volume":"82","author":"Anafi","year":"1993","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-319-04843-7_16","article-title":"Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223","volume":"804","author":"Anderson","year":"2014","journal-title":"Adv. Exp. Med. Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S","volume":"11","author":"Arcamone","year":"1969","journal-title":"peucetius var. caesius. Biotechnol. Bioeng"},{"key":"B12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1017\/S0007087416001175","article-title":"A pathology of progress? Locating the historiography of cancer","volume":"49","author":"Arnold-Forster","year":"2016","journal-title":"Br. J. Hist. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: a potential therapeutic target in trypanosomes","volume":"210","author":"Bacchi","year":"1980","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00005-018-0507-9","article-title":"Adverse effects associated with clinical applications of CAR engineered T cells","volume":"66","author":"Badieyan","year":"2018","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J. Clin. Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov"},{"key":"B21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.6965328","article-title":"Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen","volume":"207","author":"Bernstein","year":"1980","journal-title":"Science"},{"key":"B22","first-page":"4845","article-title":"Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue","volume":"51","author":"Bissery","year":"1991","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J. Clin. Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mrrev.2018.02.003","article-title":"DNA and chromosome damage induced by bleomycin in mammalian cells: an update","volume":"775","author":"Bolz\u00e1n","year":"2018","journal-title":"Mutat. Res"},{"key":"B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/030089166805400605","article-title":"Therapy with daunomycin in chronic lymphoproliferative diseases","volume":"54","author":"Bonadonna","year":"1968","journal-title":"Tumori"},{"key":"B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"B29","volume-title":"The Edwin Smith Surgical Papyrus","author":"Breasted","year":"1930"},{"key":"B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0027-5107(90)90145-T","article-title":"The early history of the biological alkylating agents, 1918\u20131968","volume":"233","author":"Brookes","year":"1990","journal-title":"Mutat. Res"},{"key":"B31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1042\/bj0770478","article-title":"The reaction of mustard gas with nucleic acids in vitro and in vivo","volume":"77","author":"Brookes","year":"1960","journal-title":"Biochem. J"},{"key":"B32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1042\/bj0800496","article-title":"The reaction of mono- and di-functional alkylating agents with nucleic acids","volume":"80","author":"Brookes","year":"1961","journal-title":"Biochem. J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur. J. Intern. Med"},{"key":"B34","volume-title":"The Papyrus Ebers","author":"Bryan","year":"1930"},{"key":"B35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"B36","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"B37","first-page":"13","article-title":"Guglielmo Corrado Roentgen e la scoperta dei raggi X","author":"Busacchi","year":"2015","journal-title":"IL Giornale Ital. Radiol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7861\/clinmedicine.12-4-381","article-title":"Molecular radiotherapy","volume":"12","author":"Buscombe","year":"2012","journal-title":"Clin. Med. (Lond)"},{"key":"B39","volume-title":"Medicine and the Five Senses","author":"Bynum","year":"2005"},{"key":"B40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10534-018-0123-5","article-title":"Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer","volume":"31","author":"Cao","year":"2018","journal-title":"Biometals"},{"key":"B41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"Carew","year":"2011","journal-title":"Target Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/13543776.2015.1056736","article-title":"5-Fluorouracil derivatives: a patent review (2012\u20132014)","volume":"25","author":"Carrillo","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"B43","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci","volume":"89","author":"Carter","year":"1992","journal-title":"U.S.A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5301\/tj.5000507","article-title":"The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use","volume":"2016","author":"Cassinelli","year":"2016","journal-title":"Tumori"},{"key":"B45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B46","first-page":"1023","article-title":"Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab","volume":"1020","author":"Chen","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrc1547","article-title":"Bleomycins: towards better therapeutics","volume":"5","author":"Chen","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.4161\/cc.7.4.5313","article-title":"Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs","volume":"62","author":"Chen","year":"2002","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0128152","DOI":"10.1371\/journal.pone.0128152","article-title":"Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS ONE"},{"key":"B50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13139-017-0509-2","article-title":"Treatment of bone metastasis with bone-targeting radiopharmaceuticals","volume":"52","author":"Choi","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s13139-009-0016-1","article-title":"Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma","volume":"44","author":"Chung","year":"2010","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"B52","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"B53","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B55","first-page":"714","article-title":"Sur la radioactivit\u00e9 provoqu\u00e9e par les rayons de B\u00e9cquerel","volume":"129","author":"Curie","year":"1899","journal-title":"Comp. Rendus Acad. Sci."},{"key":"B56","first-page":"3034","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/978-1-4939-7398-9_39","article-title":"Polyamines and cancer","volume":"1694","author":"Damiani","year":"2018","journal-title":"Methods Mol. Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/0-306-46843-3_53","article-title":"6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity","volume":"486","author":"De Abreu","year":"2000","journal-title":"Adv. Exp. Med. Biol"},{"key":"B59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/030089167305900102","article-title":"Therapy of metastatic mammary carcinoma with cyclophosphamide, methotrex ate, vincristine and fluorouracil","volume":"59","author":"De Lena","year":"1973","journal-title":"Tumori"},{"key":"B60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin's disease","volume":"73","author":"De Vita","year":"1970","journal-title":"Ann. Intern. Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fonc.2016.00141","article-title":"Modern radiotherapy concepts and the impact of radiation on immune activation","volume":"6","author":"Deloch","year":"2016","journal-title":"Front. Oncol"},{"key":"B62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/030089166304900305","article-title":"Daunomycin: a new antibiotic with antitumor activity","volume":"49","author":"Di Marco","year":"1963","journal-title":"Tumori"},{"key":"B63","first-page":"33","article-title":"Adriamycin (NSC-123,127): a new antibiotic with antitumor activity","volume":"53","author":"Di Marco","year":"1969","journal-title":"Cancer Chemother. Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1517\/14712590802517970","article-title":"Oncophage: step to the future for vaccine therapy in melanoma","volume":"8","author":"di Pietro","year":"2008","journal-title":"Expert Opin. Biol. Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10549-015-3383-6","article-title":"A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer","volume":"151","author":"Diaby","year":"2015","journal-title":"Breast Cancer Res. Treat"},{"key":"B66","first-page":"73","article-title":"Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies","volume":"5","author":"Dillman","year":"1986","journal-title":"J. Biol. Response Mod."},{"key":"B67","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"29271","DOI":"10.1038\/srep29271","article-title":"A dinosaurian facial deformity and the first occurrence of ameloblastoma in the fossil record","volume":"6","author":"Dumbravbrevea","year":"2016","journal-title":"Sci. Rep"},{"key":"B69","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000280403","article-title":"The effect of alpha-difluoromethyl-ornithine on tumor growth, acute phase reactants, beta-2-microglobulin and hydroxyproline in kidney and bladder carcinomas","volume":"36","author":"Dunzendorfer","year":"1981","journal-title":"Urol. Int"},{"key":"B70","volume-title":"Ebers Papyrus","year":"1875"},{"key":"B71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"B72","unstructured":"Guideline on Development, Production, Characterization and Specification for Monoclonal Antibodies and Related Products2016"},{"key":"B73","unstructured":"Guideline on the Evaluation of Anticancer Medicinal Products in Man2017"},{"key":"B74","first-page":"997","article-title":"Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma","volume":"67","author":"Evans","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/ijc.29134","article-title":"A brief history of cancer: age-old milestones underlying our current knowledge database","volume":"136","author":"Faguet","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S141491","article-title":"Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma","volume":"12","author":"Faiena","year":"2018","journal-title":"Drug Des. Devel. Ther"},{"key":"B77","first-page":"612","article-title":"Clinical experience with nitrogen mustard","volume":"48","author":"Faloon","year":"1948","journal-title":"N. Y. State J. Med"},{"key":"B78","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic antagonist, 4-aminopteroylglutamic acid (aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.2174\/138161212800626210","article-title":"Targeting mTOR pathways in human malignancies","volume":"18","author":"Fasolo","year":"2012","journal-title":"Curr. Pharm. Des"},{"key":"B80","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4161\/mabs.29089","article-title":"Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer","volume":"6","author":"Fauvel","year":"2014","journal-title":"MAbs"},{"key":"B81","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B82","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov"},{"key":"B84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin. Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"272","DOI":"10.15386\/cjmed-492","article-title":"Iron, inflammation and invasion of cancer cells","volume":"88","author":"Fischer-Fodor","year":"2015","journal-title":"Clujul. Med"},{"key":"B87","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00002371-199705000-00007","article-title":"Points to consider in the manufacture and testing of monoclonal antibody products for human use","volume":"20","year":"1997","journal-title":"J. Immunother"},{"key":"B88","first-page":"1310","article-title":"Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC","volume":"46","author":"Forrer","year":"2005","journal-title":"J. Nucl. Med"},{"key":"B89","first-page":"6523","article-title":"Curative cancer chemotherapy","volume":"45","author":"Frei","year":"1985","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/ja01632a006","article-title":"Preparation of N-phosphorylated derivatives of bis-\u03b2-chloroethylamine","volume":"76","author":"Friedman","year":"1954","journal-title":"J. Am. Chem. Soc"},{"key":"B92","volume-title":"Opera Omnia","year":"1565"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-causemortality, and cause-specific mortality for 249causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrc1454","article-title":"Polyamines and cancer: old molecules, new understanding","volume":"4","author":"Gerner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"B97","first-page":"285","article-title":"Therapeutic applications of chemical warfare agents","volume":"5","author":"Gilman","year":"1946","journal-title":"Fed. Proc"},{"key":"B98","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9610(63)90232-0","article-title":"The initial clinical trial of nitrogen mustard","volume":"105","author":"Gilman","year":"1963","journal-title":"Am. J. Surg"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.respol.2016.01.007","article-title":"The revolution re-visited: clinical and genetics research paradigms and the productivity paradox in drug discovery","volume":"45","author":"Gittelman","year":"2016","journal-title":"Res. Pol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer Groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1080\/10428194.2017.1376743","article-title":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study","volume":"59","author":"Goldschmidt","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B102","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J. Am. Med. Assoc"},{"key":"B103","first-page":"186","article-title":"Rhabdomyosarcoma of the prostate in a child; first 5-year survival. (Combined treatment by preoperative, local irradiation; actinomycin D; intra-arterial nitrogen mustard and hypothermia; radical surgery and ureterosigmoidostomy)","volume":"59","author":"Goodwin","year":"1967","journal-title":"Trans. Am. Assoc. Genitourin. Surg"},{"key":"B104","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol"},{"key":"B105","first-page":"127","article-title":"Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity","volume":"21","author":"Gross","year":"1989","journal-title":"Transplant. Proc."},{"key":"B106","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1148\/21.2.156","article-title":"Priority in the therapeutic use of X-rays","author":"Grubb\u00e9","year":"1933","journal-title":"Radiology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.retram.2018.03.004","article-title":"Beginning the CAR T cell therapy revolution in the US and EU","volume":"66","author":"Grupp","year":"2018","journal-title":"Curr. Res. Transl. Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"114101","DOI":"10.1118\/1.4897240","article-title":"Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods","volume":"41","author":"Guerra Liberal","year":"2014","journal-title":"Med. Phys"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000437178","article-title":"Immune checkpoint inhibitors","volume":"42","author":"Haanen","year":"2015","journal-title":"Prog. Tumor Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"bcr0120113793","DOI":"10.1136\/bcr.01.2011.3793","article-title":"Selective internal radiation therapy with 90Y-SIR-Spheres microspheres for non-resectable colorectal metastases in the liver","volume":"2011","author":"Hadaki","year":"2011","journal-title":"BMJ Case Rep."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J. Clin. Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cncr.25553","article-title":"A note from history: landmarks in history of cancer, part 1","volume":"117","author":"Hajdu","year":"2011","journal-title":"Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/cncr.29955","article-title":"Pathfinders in oncology from ancient times to the end of the middle ages","volume":"122","author":"Hajdu","year":"2016","journal-title":"Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/cncr.30590","article-title":"Pathfinders in oncology from the end of the Middle Ages to the beginning of the 19th century","volume":"123","author":"Hajdu","year":"2017","journal-title":"Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1002\/cncr.28319","article-title":"A note from history: Landmarks in history of cancer, Part 6","volume":"119","author":"Hajdu","year":"2013","journal-title":"Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000346837","article-title":"HER2 dimerization inhibitor pertuzumab\u2013mode of action and clinical data in breast cancer","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u2013a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab"},{"key":"B120","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-91442-8_8","article-title":"Everolimus","volume":"211","author":"Hasskarl","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B121","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000151369","article-title":"Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients","volume":"74","author":"Herrmann","year":"2008","journal-title":"Oncology"},{"key":"B123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI101275","article-title":"Radioactive iodine as an indicator in thyroid physiology. iv. the metabolism of iodine in graves' disease","volume":"21","author":"Hertz","year":"1942","journal-title":"J. Clin. Invest"},{"key":"B124","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.3390\/diseases6030057","article-title":"Nonviral gene therapy for cancer: a review","volume":"6","author":"Hidai","year":"2018","journal-title":"Diseases"},{"key":"B125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1954.tb40008.x","article-title":"The chemistry and biochemistry of purine analogs","volume":"60","author":"Hitchings","year":"1954","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs"},{"key":"B127","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther. Deliv"},{"key":"B128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"B130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0300-9084(98)80004-7","article-title":"Discovery of podophyllotoxins","volume":"80","author":"Imbert","year":"1998","journal-title":"Biochimie"},{"key":"B131","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-54490-3_9","article-title":"Sunitinib in the treatment of advanced solid tumors","volume":"201","author":"Imbulgoda","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2214\/AJR.17.18264","article-title":"Targeted radionuclide therapy: an evolution toward precision cancer treatment","volume":"209","author":"Jadvar","year":"2017","journal-title":"AJR Am. J. Roentgenol"},{"key":"B134","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM197411072911902","article-title":"Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma","volume":"291","author":"Jaffe","year":"1974","journal-title":"N. Engl. J. Med"},{"key":"B135","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"B136","doi-asserted-by":"crossref","first-page":"25385","DOI":"10.1016\/S0021-9258(19)74403-2","article-title":"Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line","volume":"268","author":"Jayaraman","year":"1993","journal-title":"J. Biol. Chem"},{"key":"B137","first-page":"1390","article-title":"The Vinca alkaloids: a new class of oncolytic agents","volume":"23","author":"Johnson","year":"1963","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N. Engl. J. Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.ejca.2004.04.036","article-title":"The treatment of cancer in Greek antiquity","volume":"40","author":"Karpozilos","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"B141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1998.747","article-title":"New antimetabolites in cancer chemotherapy and their clinical impact","volume":"3","author":"Kaye","year":"1998","journal-title":"Br. J. Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","article-title":"Bevacizumab: a review of its use in advanced cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"B143","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1017\/S0022215115001218","article-title":"Surgical treatment of head and neck cancers in the ancient world","volume":"129","author":"Kelly","year":"2015","journal-title":"J. Laryngol. Otol"},{"key":"B144","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/bi00865a031","article-title":"Physicochemical properties of complexes between deoxyribonucleic acid and antibiotics which affect ribonucleic acid synthesis (actinomycin, daunomycin, cinerubin, nogalamycin, chormomycin, mithramycin, and olivomycin)","volume":"5","author":"Kersten","year":"1966","journal-title":"Biochemistry"},{"key":"B145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/00016925109176998","article-title":"Nitrogen mustard therapy in Hodgkin's disease, lympho-reticulosarcomatosis and lymphatic leukaemia","volume":"36","author":"Kieler","year":"1951","journal-title":"Acta Radiol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.3816\/CLC.2004.s.019","article-title":"Cetuximab as a single agent or in combination with chemotherapy in lung cancer","volume":"6","author":"Kim","year":"2004","journal-title":"Clin. Lung Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajd.12406","article-title":"Cyclophosphamide in dermatology","volume":"58","author":"Kim","year":"2017","journal-title":"Australas J. Dermatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B151","first-page":"393","article-title":"Hypersensitivity to therapeutic murine monoclonal antibodies","volume":"79","author":"Kornbrot","year":"1994","journal-title":"Nebr. Med. J"},{"key":"B152","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00216-011-4712-1","article-title":"The contribution of Marie Sk\u0142odowska-Curie to the development of modern oncology","volume":"400","author":"Ku\u0142akowski","year":"2011","journal-title":"Anal. Bioanal. Chem"},{"key":"B155","first-page":"317","article-title":"Palliative radiotherapy with Strontium-89 in case of extended formation of skeleton metastases (author's transl)","volume":"154","author":"Kutzner","year":"1978","journal-title":"Strahlentherapie"},{"key":"B156","first-page":"1347","article-title":"Some effects of cyclophosphamide (cytoxan) on normal mice and mice with L1210 leukemia","volume":"23","author":"Lane","year":"1959","journal-title":"J. Natl. Cancer Inst"},{"key":"B157","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1471-2466-14-192","article-title":"A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)","volume":"14","author":"Lange","year":"2014","journal-title":"BMC Pulm. Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ijo.2018.4287","article-title":"Cutaneous melanoma: from pathogenesis to therapy","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol"},{"key":"B160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1056\/NEJM195807102590204","article-title":"Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists","volume":"259","author":"Li","year":"1958","journal-title":"N. Engl. J. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1081\/CNV-100106152","article-title":"What is the \u201cbest\u201d platinum: cisplatin, carboplatin, or oxaliplatin?","volume":"19","author":"Lokich","year":"2001","journal-title":"Cancer Invest"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","first-page":"934963","DOI":"10.1155\/2015\/934963","article-title":"Antiproliferative, apoptotic, and autophagic activity of ranibizumab, bevacizumab, pegaptanib, and aflibercept on fibroblasts: implication for choroidal neovascularization","volume":"2015","author":"Lytvynchuk","year":"2015","journal-title":"J. Ophthalmol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov"},{"key":"B169","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.advenzreg.2009.10.016","article-title":"Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells","volume":"50","author":"McCubrey","year":"2010","journal-title":"Adv. Enzyme Regul."},{"key":"B172","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"B173","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000203749","article-title":"Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid)","volume":"4","author":"Meyer","year":"1950","journal-title":"Acta Haematol"},{"key":"B174","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/ajhp\/55.22.2326","article-title":"Progress in breast cancer treatment: prevention, new therapies come to forefront","volume":"55","author":"Miller","year":"1998","journal-title":"Am. J. Health Syst. Pharm"},{"key":"B175","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin"},{"key":"B176","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N. Engl. J. Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/j.jmb.2015.06.020","article-title":"Remaining mysteries of molecular biology: the role of polyamines in the cell","volume":"427","author":"Miller-Fleming","year":"2015","journal-title":"J. Mol. Biol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"B179","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-291X(84)90454-6","article-title":"Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26","volume":"122","author":"Minocha","year":"1984","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B180","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"B182","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09553002.2017.1376764","article-title":"Radiation fractionation: the search for isoeffect relationships and mechanisms","volume":"2","author":"Moulder","year":"2017","journal-title":"Int. J. Radiat. Biol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"B185","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin's disease","volume":"27","author":"Moxley","year":"1967","journal-title":"Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"B187","volume-title":"The Emperor of All Maladies: A Biography of Cancer","author":"Mukherjee","year":"2011"},{"key":"B188","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12885-018-4183-2","article-title":"Long-term trastuzumab (Herceptin\u00ae) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer","volume":"18","author":"M\u00fcller","year":"2018","journal-title":"BMC Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/jm401174a","article-title":"Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine","volume":"57","author":"Muth","year":"2014","journal-title":"J. Med. Chem"},{"key":"B190","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res"},{"key":"B191","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/000313481608200607","article-title":"The history of multimodal treatment of Wilms' tumor","volume":"82","author":"Nakayama","year":"2016","journal-title":"Am. Surg"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"B193","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B194","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"B195","first-page":"350","article-title":"Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer","volume":"12","author":"Niculescu-Duvaz","year":"2010","journal-title":"Curr. Opin. Mol. Ther"},{"key":"B196","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1749-6632.1958.tb54906.x","article-title":"Role of chance observations in chemotherapy: Vinca rosea","volume":"76","author":"Noble","year":"1958","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"B197","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1021\/np030498t","article-title":"Camptothecin and taxol: historic achievements in natural products research","volume":"67","author":"Oberlies","year":"2004","journal-title":"J. Nat. Prod"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","article-title":"Taxane anticancer agents: a patent oerspective","volume":"26","author":"Ojima","year":"2016","journal-title":"Expert Opin. Ther. Pat"},{"key":"B199","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.1983.1.9.582","article-title":"Monoclonal antibodies in cancer therapy","volume":"19","author":"Oldham","year":"1983","journal-title":"J. Clin. Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2741\/1909","article-title":"Monoclonal antibody therapy","volume":"11","author":"O'Mahony","year":"2006","journal-title":"Front. Biosci"},{"key":"B201","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","article-title":"Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents","volume":"65","author":"O'Reilly","year":"2010","journal-title":"Cancer Chemother. Pharmacol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1245\/s10434-009-0886-6","article-title":"Ancient Greek and Greco-Roman methods in modern surgical treatment of cancer","volume":"17","author":"Papavramidou","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"B203","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J. Clin. Oncol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.21873\/anticanres.12040","article-title":"Monoclonal antibodies for the treatment of cancer","volume":"37","author":"Pento","year":"2017","journal-title":"Anticancer Res"},{"key":"B205","first-page":"2887","article-title":"Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients","volume":"9","author":"Peralba","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"B207","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11523-013-0271-z","article-title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","volume":"8","author":"Poulin-Costello","year":"2013","journal-title":"Target Oncol"},{"key":"B208","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2013.07.006","article-title":"From old alkylating agents to new minor groove binders","volume":"89","author":"Puyo","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/10428194.2014.927461","article-title":"Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab","volume":"56","author":"Quackenbush","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"B211","doi-asserted-by":"publisher","first-page":"e000236","DOI":"10.1136\/esmoopen-2017-000236","article-title":"Anti-PD-1\/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials","volume":"2","author":"Ramos-Esquivel","year":"2017","journal-title":"ESMO Open"},{"key":"B212","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B213","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jama.1946.02870250010003","article-title":"Nitrogen mustards in the treatment of neoplastic disease; official statement","volume":"131","author":"Rhoads","year":"1946","journal-title":"J. Am. Med. Assoc"},{"key":"B214","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"B215","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Robert","year":"2001","journal-title":"J. Clin. Oncol"},{"key":"B216","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.3.59.227","article-title":"On a new kind of rays","volume":"3","author":"R\u00f6ntgen","year":"1896","journal-title":"Science"},{"key":"B217","first-page":"103","article-title":"Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers","volume":"12","author":"Rosen","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance\u2013the story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"B219","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"B220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans\u2013immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N. Engl. J. Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1517\/14740338.4.6.1051","article-title":"Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients","volume":"4","author":"Rossi","year":"2005","journal-title":"Expert Opin. Drug Saf"},{"key":"B223","volume-title":"Farmacologia: Principi di Base e Applicazioni Terapeutiche, 3rd Edn","author":"Rossi","year":"2016"},{"key":"B224","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1749-6632.1996.tb26397.x","article-title":"The current status of irinotecan (CPT-11) in the United States","volume":"803","author":"Rothenberg","year":"1996","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"B225","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00114-003-0473-9","article-title":"Epidemiologic study of tumors in dinosaurs","volume":"90","author":"Rothschild","year":"2003","journal-title":"Naturwissenschaften"},{"key":"B226","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3892\/ijo.2014.2481","article-title":"Emerging targeted therapies for melanoma treatment (review)","volume":"45","author":"Russo","year":"2014","journal-title":"Int. J. Oncol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1158\/1535-7163.MCT-17-0673","article-title":"Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers","volume":"17","author":"Sakamuri","year":"2018","journal-title":"Mol. Cancer Ther"},{"key":"B228","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3389\/fphar.2018.00856","article-title":"MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA","volume":"9","author":"Salemi","year":"2018","journal-title":"Front. Pharmacol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J. Clin. Oncol"},{"key":"B230","doi-asserted-by":"crossref","DOI":"10.5913\/2012017","volume-title":"The Edwin Smith Papyrus: Updated Translation of the Trauma Treatise and Modern Medical Commentaries","author":"Sanchez","year":"2012"},{"key":"B231","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"key":"B232","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol"},{"key":"B233","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun"},{"key":"B234","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol"},{"key":"B235","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"B236","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1021\/jo01053a060","article-title":"Imidazole I. Coupling reactions of 5-diazoimidazole-4-carboxamide","volume":"27","author":"Shealy","year":"1962","journal-title":"J. Org. Chem."},{"key":"B237","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF00918679","article-title":"Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic","volume":"11","author":"Shepard","year":"1991","journal-title":"J. Clin. Immunol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2967\/jnumed.112.105148","article-title":"The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0","volume":"53","author":"Silberstein","year":"2012","journal-title":"J. Nucl. Med"},{"key":"B239","first-page":"294","article-title":"Observations on the anticancer activity of 6-mercaptopurine","volume":"14","author":"Skipper","year":"1954","journal-title":"Cancer Res"},{"key":"B240","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"B241","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.2013.50.8952","article-title":"Assessing progress in reducing the burden of cancer mortality, 1985\u20132005","volume":"32","author":"Soneji","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1586\/14737140.6.9.1163","article-title":"Sipuleucel-T (APC8015) for prostate cancer","volume":"6","author":"So-Rosillo","year":"2006","journal-title":"Expert Rev. Anticancer Ther"},{"key":"B243","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1210\/jcem.86.7.7641","article-title":"Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy","volume":"86","author":"Spitzweg","year":"2001","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B244","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-91442-8_1","article-title":"Erlotinib","volume":"211","author":"Steins","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B246","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"B247","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00259-010-1391-7","article-title":"Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma","volume":"37","author":"Sudbrock","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/1948-5956.100000e2","article-title":"History of cancer, ancient and modern treatment methods","volume":"1","author":"Sudhakar","year":"2009","journal-title":"J. Cancer Sci. Ther"},{"key":"B249","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/1097-0142(194909)2:5<877::AID-CNCR2820020520>3.0.CO;2-0","article-title":"Bone-marrow changes in man after treatment with aminopterin, amethopterin, and aminoanfol; with special reference to megaloblastosis and tumor remission","volume":"2","author":"Thiersch","year":"1949","journal-title":"Cancer"},{"key":"B250","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4103\/0973-1482.106526","article-title":"Antimetabolites: established cancer therapy","volume":"8","author":"Tiwari","year":"2012","journal-title":"J. Cancer Res. Ther"},{"key":"B251","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","article-title":"Targeted therapy in cancer","volume":"76","author":"Tsimberidou","year":"2015","journal-title":"Cancer Chemother. Pharmacol"},{"key":"B252","first-page":"1031","article-title":"Hippocrates (ca 460-370 BC) on nasal cancer","volume":"21","author":"Tsoucalas","year":"2016","journal-title":"J. B.U.O.N"},{"key":"B253","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1038\/sj.onc.1204704","article-title":"STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications","volume":"20","author":"Tuveson","year":"2001","journal-title":"Oncogene"},{"key":"B254","first-page":"200","article-title":"New antibiotics, bleomycin A and B","volume":"19","author":"Umezawa","year":"1966","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B255","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00280-015-2903-8","article-title":"Antimitotic drugs in the treatment of cancer","volume":"76","author":"van Vuuren","year":"2015","journal-title":"Cancer Chemother. Pharmacol"},{"key":"B256","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B257","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B258","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.gt.3301084","article-title":"Cancer gene therapy: hard lessons and new courses","volume":"7","author":"Vile","year":"2000","journal-title":"Gene Ther"},{"key":"B259","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/156800910790980241","article-title":"Cetuximab: from bench to bedside","volume":"10","author":"Vincenzi","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"B260","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","article-title":"Lapatinib","volume":"211","author":"Voigtlaender","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B261","first-page":"15","article-title":"Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers","volume":"20","author":"Vokes","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"B262","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann. Oncol"},{"key":"B263","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/cr9804386","article-title":"Therapeutic radiopharmaceuticals","volume":"99","author":"Volkert","year":"1999","journal-title":"Chem. Rev"},{"key":"B264","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc"},{"key":"B265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib mesylate","volume":"212","author":"Waller","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B266","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem. Soc"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12272-017-0979-x","article-title":"The combination of curcumin and 5-fluorouracil in cancer therapy","volume":"41","author":"Wei","year":"2018","journal-title":"Arch. Pharm. Res"},{"key":"B268","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol"},{"key":"B269","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/bc960033x","article-title":"Synthesis and nca-radioiodination of arylstannyl-cobalamin conjugates. Evaluation of aryliodo-cobalamin conjugate binding to transcobalamin II and biodistribution in mice","volume":"7","author":"Wilbur","year":"1996","journal-title":"Bioconjug. Chem"},{"key":"B270","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B271","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-13-1896","article-title":"Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases","volume":"19","author":"Wissing","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"B272","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archinte.1955.04430010075008","article-title":"Clinical evaluation of puromycin in human neoplastic disease","volume":"96","author":"Wright","year":"1955","journal-title":"AMA Arch. Intern. Med"},{"key":"B273","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","article-title":"Allosteric small-molecule kinase inhibitors","volume":"156","author":"Wu","year":"2015","journal-title":"Pharmacol. Ther"},{"key":"B274","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.18632\/oncotarget.24179","article-title":"The development of CAR design for tumor CAR-T cell therapy","volume":"9","author":"Xu","year":"2018","journal-title":"Oncotarget"},{"key":"B275","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"B276","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.04.001","article-title":"CRISPR\/Cas9 for cancer research and therapy","author":"Zhan","year":"2018","journal-title":"Semin. Cancer Biol"},{"key":"B278","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1586\/14737159.2014.866039","article-title":"The application of monoclonal antibodies in cancer diagnosis","volume":"14","author":"Zhang","year":"2014","journal-title":"Expert Rev. Mol. Diagn"},{"key":"B279","first-page":"65","article-title":"Tumor pretargeting for radioimmunodetection and radioimmunotherapy","volume":"39","author":"Zhu","year":"1998","journal-title":"J. Nucl. Med"},{"key":"B280","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:34:56Z","timestamp":1775266496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":280,"alternative-id":["10.3389\/fphar.2018.01300"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01300","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"article-number":"1300"}}